Piper Jaffray reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Monday, March 12th. Piper Jaffray currently has a $76.12 price objective on the biotechnology company’s stock, down from their prior price objective of $83.00.
Several other brokerages have also recently issued reports on SRPT. SunTrust Banks raised their target price on shares of Sarepta Therapeutics to $76.00 and gave the stock a buy rating in a report on Thursday, March 8th. Morgan Stanley raised their target price on shares of Sarepta Therapeutics from $63.00 to $64.00 and gave the stock an overweight rating in a report on Tuesday, March 6th. Credit Suisse Group set a $81.00 target price on shares of Sarepta Therapeutics and gave the stock a buy rating in a report on Friday, March 2nd. Barclays reiterated a hold rating and issued a $55.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, January 23rd. Finally, William Blair reiterated an outperform rating on shares of Sarepta Therapeutics in a report on Monday, February 5th. Five research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $76.40.
NASDAQ SRPT traded down $1.12 on Monday, reaching $71.74. 759,523 shares of the company’s stock traded hands, compared to its average volume of 1,565,732. Sarepta Therapeutics has a 12 month low of $28.14 and a 12 month high of $84.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 13.91 and a quick ratio of 12.96. The stock has a market capitalization of $4,805.80, a P/E ratio of -43.74 and a beta of 1.29.
A number of institutional investors have recently made changes to their positions in SRPT. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Sarepta Therapeutics by 39.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 977 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its position in Sarepta Therapeutics by 140.9% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 2,493 shares during the period. Prentiss Smith & Co. Inc. purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $199,000. Brighton Jones LLC purchased a new position in Sarepta Therapeutics during the third quarter valued at $211,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $217,000. 84.98% of the stock is owned by institutional investors and hedge funds.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.